Topical nepafenec in eyes with noncentral diabetic macular edema.
| Autor: | Friedman SM; Florida Retina Consultants, Lakeland, Florida; †Jaeb Center for Health Research, Tampa, Florida; ‡Paducah Retinal Center, Paducah, Kentucky; §Elman Retina Group, P.A., Philadelphia, Pennsylvania; ¶Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland; **North Shore University Health System, Pritzker School of Medicine, University of Chicago, Glenview, Illinois; and ††Feinberg School of Medicine, Northwestern University, Chicago, Illinois., Almukhtar TH, Baker CW, Glassman AR, Elman MJ, Bressler NM, Maker MP, Jampol LM, Melia M |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Retina (Philadelphia, Pa.) [Retina] 2015 May; Vol. 35 (5), pp. 944-56. |
| DOI: | 10.1097/IAE.0000000000000403 |
| Abstrakt: | Purpose: To evaluate the effect of a topical, nonsteroidal antiinflammatory drug, nepafenac 0.1%, in eyes with noncentral diabetic macular edema. Methods: Multicenter, double-masked randomized trial. Individuals with good visual acuity and noncentral-involved diabetic macular edema were randomly assigned to nepafenac 0.1% (N = 61) or placebo (nepafenac vehicle, N = 64) 3 times a day for 12 months. The primary outcome was mean change in optical coherence tomography retinal volume at 12 months. Results: Mean baseline retinal volume was 7.8 mm. At 12 months, in the nepafenac and placebo groups respectively, mean change in retinal volume was -0.03 mm and -0.02 mm (treatment group difference: -0.02, 95% confidence interval: -0.27 to 0.23, P = 0.89). Central-involved diabetic macular edema was present in 7 eyes (11%) and 9 eyes (14%) at the 12-month visit (P = 0.79), respectively. No differences in visual acuity outcomes were identified. One study participant developed a corneal melt after using nepafenac in the nonstudy eye, which had a history of severe dry eye. No additional safety concerns were evident. Conclusion: In eyes with noncentral diabetic macular edema and good visual acuity, topical nepafenac 0.1% 3 times daily for 1 year likely does not have a meaningful effect on optical coherence tomography-measured retinal thickness. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|